Substandard Medicines Pulled From Nepali Market
Summary
The Department of Drug Administration has recalled several substandard medicines from the Nepali market after laboratory tests found they failed quality standards. Health officials say weak monitoring and shortages of inspection staff are allowing unsafe drugs to reach consumers.
Key Points
- The Department of Drug Administration has ordered the recall of multiple substandard medicines and banned their sale and distribution.
- Medicines including Winkle, Kalsigen-F, and Glipid-1 were found non-compliant after testing at the National Drug Laboratory.
- The article says Nepal’s drug regulatory system is understaffed, with only 24 inspection personnel for about 26,000 drug stores and pharmacies.
- Experts warn that weak monitoring of the market and border checkpoints increases the risk of unsafe medicines reaching patients.